Physician profile
Patrick Stovall
NPI 1376004549
$458.20
in general payments reported to CMS, 2019-2025
11 companies · $40.68 in 2025
The $40.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.35 · 2021: $74.45 · 2023: $77.80 · 2024: $227 · 2025: $40.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.28 | 2023-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $60.58 | 2023-2025 | Terlivaz |
| Astrazeneca Pharmaceuticals Lp | $58.54 | 2021 | |
| Pfizer INC. | $39.82 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $28.89 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $28.55 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $27.89 | 2024 | |
| Abbvie INC. | $27.83 | 2024 | |
| Ucb, INC. | $20.42 | 2023 | Briviact |
| Boston Scientific Corporation | $15.96 | 2024 | Watchman Access System |
| Neurocrine Biosciences, INC. | $14.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stovall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.